Asperia Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.40 M
- Revenue Growth -15.45%
- Profit Growth 106.12%
- Ebitda 57.77%
- Net Worth 33.60%
- Total Assets -9.67%
About Asperia Lifesciences
Asperia Lifesciences Private Limited (ALPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 December 2018 (Six years and two months 6 days old ). Its registered office is in Jaipur, Rajasthan, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.40 M.
Pankaj Joshi, Himanshi, Mohita Pareek, and One other member serve as directors at the Company.
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999RJ2018PTC063315
- Company No.
063315
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Asperia Lifesciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pankaj Joshi  | Director | 17-Dec-2018 | Current |
| Himanshi | Director | 17-Dec-2018 | Current |
| Mohita Pareek | Director | 17-Dec-2018 | Current |
| Kamal Arora | Director | 17-Dec-2018 | Current |
Financial Performance of Asperia Lifesciences.
Asperia Lifesciences Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 15.45% decrease. The company also saw a substantial improvement in profitability, with a 106.12% increase in profit. The company's net worth Soared by an impressive increase of 33.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Asperia Lifesciences?
In 2021, Asperia Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹4.40 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.44 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 May 2023 | Others | ₹1.40 M | Open |
| 18 Jun 2022 | Others | ₹3.00 M | Open |
How Many Employees Work at Asperia Lifesciences?
Unlock and access historical data on people associated with Asperia Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Asperia Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Asperia Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.